CA Patent

CA2595218C — Indole derivatives having inhibitory activity against sodium-dependent glucose transporter

Assigned to Tanabe Pharma Corp · Expires 2013-06-18 · 13y expired

What this patent protects

The present invention provides novel indole derivatives of formula (I) and pharmaceutically acceptable salts thereof: wherein R1 is a halogen, or alkyl, R2 is hydrogen, or halogen, Ar is phenyl, or thienyl, which may be substituted with halogen, alkyl, alkoxy, alkylthio, etc. Th…

USPTO Abstract

The present invention provides novel indole derivatives of formula (I) and pharmaceutically acceptable salts thereof: wherein R1 is a halogen, or alkyl, R2 is hydrogen, or halogen, Ar is phenyl, or thienyl, which may be substituted with halogen, alkyl, alkoxy, alkylthio, etc. These compounds have utility for example as inhibitors of sodium-dependent glucose transporters (SGLT). (see formula I)

Drugs covered by this patent

Patent Metadata

Patent number
CA2595218C
Jurisdiction
CA
Classification
—
Expires
2013-06-18
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.